Navigation Links
Publication of Shire plc's Annual Report 2008
Date:3/25/2009

eet regulatory requirements. The Group is also subject to the risk that suppliers will not be able to meet the quantities needed to meet market requirements

The development and approval of the Group's products depends on the ability to procure active ingredients and special packaging materials from sources approved by regulatory authorities. As the marketing approval process requires manufacturers to specify their own proposed suppliers of active ingredients and special packaging materials in their applications, regulatory approval of a new supplier would be required if active ingredients or such packaging materials were no longer available from the supplier specified in the marketing approval. The need to qualify a new supplier could delay the Group's development and commercialization efforts.

The Group uses bovine-derived serum sourced from New Zealand and North America in the manufacturing processes for REPLAGAL and ELAPRASE. The discovery of additional cattle in North America or the discovery of cattle in New Zealand with bovine spongiform encephalopathy, or mad cow disease, could cause the regulatory agencies in some countries to impose restrictions on these products, or prohibit the Group from using these products at all in such countries.

The actions of certain customers can affect the Group's ability to sell or market products profitably, as well as impact net sales and growth comparisons

A small number of large wholesale distributors control a significant share of the US and European markets. In 2008, for example, approximately 56% of the Group's product sales were attributable to two customers; McKesson Corp. and Cardinal Health, Inc. In the event of financial failure of any of these customers, the Group may suffer financial loss and a decline in revenues and earnings. In addition, the number of independent drug stores and small chains has decreased as retail pharmacy consolida
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
4. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
5. New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases
6. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
7. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
8. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
9. Publication on Tregitopes in Blood Journal of October 2008
10. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
11. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company ... to manufacture proteins including biosimilar therapeutics, today provided ... the second quarter ended June 30, 2014. ... public offering, we have the capital to continue ... our proprietary protein expression platform," stated Bertrand C. ...
(Date:8/29/2014)... are based on electrons, but one of the most ... i.e. circuits based on light (photons) instead of electrons. ... a stream of single photons and control their direction. ... attempts to achieve this control, but now scientists at ... steady stream of photons emitted one at a time ...
(Date:8/29/2014)... August 29, 2014 The global ... billion in 2019. It is expected to grow ... 2019, and was valued at $1.8 billion in ... Transparency Market Research. , For more information regarding ... . , The research report, titled “Companion Diagnostics ...
(Date:8/29/2014)... According to a new market report published ... market was valued at USD 3,754.6 million in 2012 and ... 2019at a CAGR of 5.9% from 2013 to 2019. , ... is afflicted by bone and joint disorders, and this number ... has and will continue to increase the demand for orthobiologics. ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Breakthrough in light sources for new quantum technology 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3
...  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Neurocrine Biosciences, will be presenting at the 24th Annual Roth ... takes place on Tuesday, March 13 at 2:00 p.m. Pacific ... webcast and may be accessed on the Company,s website at ...
... ATLANTA, March 7, 2012 Harriet L. Robinson, Ph.D., ... a biotech company specializing in the development of HIV/AIDS ... scientists may be one step closer to a vaccine ... study results were unveiled by Dr. Robinson during a ...
... BETHESDA, Md., March 7, 2012   Spherix Incorporated ... innovator in biotechnology for therapy in diabetes, metabolic ... regulatory consulting services to food, supplement, biotechnology and ... its drug candidates, SPX-106T, arrested development and reduced ...
Cached Biology Technology:GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI) 2GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI) 3GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI) 4SPX-106T Arrests Development of Atherosclerotic Plaques in Mouse Model of Cardiovascular Disease 2SPX-106T Arrests Development of Atherosclerotic Plaques in Mouse Model of Cardiovascular Disease 3SPX-106T Arrests Development of Atherosclerotic Plaques in Mouse Model of Cardiovascular Disease 4
(Date:8/29/2014)... made some surprising discoveries about the body,s initial ... (SIV), the team found that specialized cells in ... to viral invasion and are the source of ... beta (IL-1β). , Though aimed at the ... gut epithelium that provides a barrier to protect ...
(Date:8/29/2014)... Scientists at the Barshop Institute for Longevity and ... the UT Health Science Center at San Antonio, have ... the longest-lived rodent, the naked mole rat. , ... naked mole rats protects and alters the activity of ... proteins. , The factor also protects proteasome function in ...
(Date:8/29/2014)... recently, little has been known about what genetic changes ... of scientists, one of whom is a University of ... that genes controlling the development of the brain and ... The study was published Aug. 28 in Science ... is online at http://www.sciencemag.org/ ., The domestication of ...
Breaking Biology News(10 mins):The early cost of HIV 2Factor in naked mole rat's cells enhances protein integrity 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3
... Researchers at the David Geffen School of Medicine at ... proteins known as sodium glucose co-transporters (SGLTs), which pump ... the treatment of chronic diarrhea via oral rehydration therapy, ... The solution of the SGLT structure will accelerate development ...
... have provided vital information to relief workers in Myanmar ... devastating Cyclone Nargis that hit the country on 2 ... the UN Office for the Coordination of Humanitarian Affairs ... Disasters, referred to as ,the Charter, for support by ...
... Want to slow the signs of aging and live longer? ... could be a promising strategy. Calorie restriction has ... and mice. While scientists do not know how calorie restriction ... that it slows aging by decreasing a thyroid hormone, triiodothyronine ...
Cached Biology News:UCLA researchers clarify function of glucose transport molecule 2Extended cyclone relief efforts aided from space 2Extended cyclone relief efforts aided from space 3Looking for the Founatain of Youth? Cut your calories, research suggests 2